within Pharmacolibrary.Drugs.ATC.J;

model J01EB06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.001,
    adminDuration  = 600,
    adminMass      = 2000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01EB06</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Sulfanilamide is a synthetic sulfonamide antibacterial agent, historically significant as one of the first effective systemic antibiotics. It inhibits bacterial folic acid synthesis by blocking dihydropteroate synthase. Today, sulfanilamide is rarely used clinically due to toxicity and the availability of safer alternatives. Its modern use is mainly limited to topical formulations.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for a healthy adult population based on available older sources and pharmacological class properties. No directly referenced clinical publication with full PK parameters is available for sulfanilamide.</p><h4>References</h4><ol><li><p>Ponto, LL, &amp; Schoenwald, RD (1990). Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part I). <i>Clinical pharmacokinetics</i> 18(5) 381–408. DOI:<a href=\"https://doi.org/10.2165/00003088-199018050-00004\">10.2165/00003088-199018050-00004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2185908/\">https://pubmed.ncbi.nlm.nih.gov/2185908</a></p></li><li><p>Tajima, T, Saiga, M, Yamamoto, H, Elbadawy, M, Abugomaa, A, Miura, R, Usui, T, Sasaki, K, &amp; Shimoda, M (2023). Oral pharmacokinetics of sulfadiazine and sulfamonomethoxine in female Holstein milking cows. <i>The Journal of veterinary medical science</i> 85(7) 715–720. DOI:<a href=\"https://doi.org/10.1292/jvms.23-0110\">10.1292/jvms.23-0110</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37225451/\">https://pubmed.ncbi.nlm.nih.gov/37225451</a></p></li><li><p>Cockerill, FR, &amp; Edson, RS (1991). Trimethoprim-sulfamethoxazole. <i>Mayo Clinic proceedings</i> 66(12) 1260–1269. DOI:<a href=\"https://doi.org/10.1016/s0025-6196(12)62478-1\">10.1016/s0025-6196(12)62478-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1749295/\">https://pubmed.ncbi.nlm.nih.gov/1749295</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01EB06;
